Preventing Early Drug Discontinuation

Case Study

IQVIA Predicted 81% of Multiple Sclerosis Patients Likely to Discontinue Treatment Early

Nov 03, 2022

Library
Preventing Early Drug Discontinuation

Identifying key patient journey events that lead to early product discontinuation is an important part of product strategy – especially for treatments of chronic or long-term conditions like multiple sclerosis.

In this case study, IQVIA’s Real World Data (RWD) resources and state-of-the-art artificial intelligence (AI) and machine learning (ML) methods helped this large Biotech company to accurately identify patients at high risk of discontinuing a multiple sclerosis medication treatment.

Strategic Impact:

IQVIA's AI-powered modelling successfully predicted 81% of patients likely to discontinue treatment early
Our client was able to formulate new business strategies to address identified issues and improve patient adherence, helping to realize their product’s true value

Have questions? Want a demonstration?

We'd love to show you how AI and Machine Learning can help you find the right patients, the right HCPs, and develop patient journey insights with precision and speed.

Just send us a message and we'll connect you to a dedicated expert who you can give you a demonstration, customized to your goals and needs.

SPEAK TO AN EXPERT

To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Strategic Impact:

Have questions? Want a demonstration?

Related solutions